HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

Rhea-AI Summary

HCW Biologics (NASDAQ: HCWB) priced a $1.6 million private placement of 618,682 units with investors that include company officers, a director and an existing stockholder. Each unit consists of one common share (or one pre-funded warrant) plus the right to receive one common stock purchase warrant, subject to stockholder approval.

HCW Biologics will issue 218,682 common shares and 400,000 pre-funded warrants at combined prices of $2.585 per share unit and $2.5849 per pre-funded warrant unit. Pre-funded warrants are immediately exercisable at $0.0001 and do not expire; common warrants, once approved and issued, will allow purchase of up to 618,682 shares at $2.585 per share for 5.5 years. Proceeds are intended to fund the HCW9302 clinical trial, IND-enabling studies for T-Cell Engager HCW11-018b and immune checkpoint inhibitor HCW11-040, and general corporate purposes. A registration rights agreement requires filing a Form S-1 within 15 trading days and seeking SEC effectiveness within 60 days; each investor’s ownership is capped at 9.99% of outstanding shares.

Positive

• $1.6 million gross proceeds from private placement financing
• 618,682 units sold, including 218,682 shares and 400,000 pre-funded warrants
• Exercise prices fixed at $2.585 for common warrants and $0.0001 for pre-funded warrants
• Net proceeds earmarked to advance HCW9302, HCW11-018b and HCW11-040 programs
• Insider participation by CEO, board chair and SVP on same terms as other investors

Negative

• Potential dilution from 218,682 new shares plus up to 1,018,682 shares via warrant exercises
• Issuance of 618,682 common warrants contingent on stockholder approval under Nasdaq Rule 5635(d)
• Resale liquidity depends on Form S-1 effectiveness within the targeted 60-day period

News Market Reaction – HCWB

-0.19% 1.6x vol

14 alerts

-0.19% Session close to close

+34.1% Peak Tracked

-3.8% Trough Tracked

$5.26M Market Cap

1.6x Rel. Volume

In the Jul 29 session, HCWB declined 0.19%, reflecting a mild negative market reaction. Argus tracked a peak move of +34.1% during that session. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Tag-specific history recorded an average move of -2.56% across 2 offerings. That record frames the s...

Analysis

Tag-specific history recorded an average move of -2.56% across 2 offerings. That record frames the stockholder-approval condition and warrant-linked issuance as the key factors to monitor; recent insider activity was Net Buying.

Key Figures

Offering size: $1.6 million Units issued: 618,682 units Common shares: 218,682 shares +5 more

8 metrics

Offering size $1.6 million Private placement

Units issued 618,682 units Private placement

Common shares 218,682 shares Issued at offering closing

Pre-funded warrants 400,000 warrants Issued in connection with the offering

Common warrants 618,682 shares underlying warrants Subject to stockholder approval

Unit purchase price $2.585 per Unit Unit with common stock and contingent Common Warrant

Common Warrant exercise price $2.585 per share Expires 5.5 years after issuance

Pre-Funded Warrant exercise price $0.0001 per share Immediately exercisable and does not expire until fully exercised

Previous Private placement,offering Reports

2 past events · Latest: May 21 (Negative)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
May 21	Private placement	Negative	+6.2%	Priced approximately $4.0 million placement with units, warrants, and clinical-development proceeds.
Nov 18	Registered direct offering	Negative	-11.3%	Priced $6.9 million registered direct offering and concurrent private placement with warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Tag-specific offering history was mixed: one offering aligned with a negative reaction and one diverged from a positive reaction, with an average move of -2.56%.

Key Terms

private placement, pre-funded warrant, common warrant, registration rights agreement, +1 more

5 terms

private placement financial

"announced the pricing of its $1.6 million private placement offering"

A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.

pre-funded warrant financial

"one pre-funded warrant to purchase one share of Common Stock"

A pre-funded warrant is a financial instrument that gives the holder the right to buy shares of a company's stock at a set price, with most of the purchase cost already paid upfront. It functions like a nearly fully paid option, allowing investors to secure shares quickly while minimizing the amount of additional money they need to invest later. This helps investors gain ownership rights efficiently, often used to avoid certain regulatory restrictions or to prepare for future stock purchases.

common warrant financial

"the right to receive one common stock purchase warrant"

A common warrant is a tradable security that gives its holder the right to buy a company’s common shares at a preset price for a limited time. It matters to investors because exercising warrants can dilute existing ownership and create leverage: holders can benefit if the stock rises above the preset price, while holders of original shares face potential reduction in their percentage stake, similar to more tickets being added to a raffle.

registration rights agreement regulatory

"entered into a registration rights agreement with the Investors"

A registration rights agreement is a contract that gives investors the option to have their ownership stakes officially registered with the government, making it easier to sell their shares later. This agreement matters because it provides investors with a clearer path to cash out their investments if they choose, offering more liquidity and confidence in their ability to sell their holdings when desired.

ind-enabling studies medical

"advance its IND-enabling studies for its T-Cell Engager"

Ind-enabling studies are early research efforts that test whether a new drug or treatment is safe and effective enough to move forward in development. They are like preliminary tests to ensure a product works as intended before investing more resources into large-scale trials. For investors, these studies are important because successful results can signal potential progress toward bringing a new product to market, impacting its future value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIRAMAR, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”), (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today announced the pricing of its $1.6 million private placement offering (the “Offering”) with a group of investors, including officers, directors and an existing stockholder of the Company, (each, and “Investor” and collectively, the “Investors”). Pursuant to a securities purchase agreement entered into with the Investors (the “Purchase Agreement”), the Company agreed to issue and sell an aggregate of 618,682 units (the “Units”), with each Unit consisting of (i) one share of the Company’s common stock, par value $0.0001 per share (“Common Stock”), or, in lieu thereof, one pre-funded warrant to purchase one share of Common Stock (a “Pre-Funded Warrant”), and (ii) the right to receive one common stock purchase warrant (a “Common Warrant”) to purchase one share of Common Stock upon, and subject to, stockholder approval of the issuance thereof.

In connection with the Offering, the Company will issue 218,682 shares of Common Stock and 400,000 Pre-Funded Warrants. Subject to stockholder approval, which the Company is obligated to seek pursuant to the terms of the Purchase Agreement, the Investors will also be entitled to receive Common Warrants to purchase up to an aggregate of 618,682 shares of Common Stock.

Hing C. Wong, Ph.D., the Company’s Founder and Chief Executive Officer, Scott Garrett, a member and the Chairman of the Company’s Board of Directors, and Lee Flowers, the Company’s Senior Vice President of Business Development, participated in the Offering on the same terms and conditions as the other Investor. The closing of the Offering is expected to occur on or about July 29, 2026, subject to the satisfaction of customary closing conditions.

The combined purchase price for each Unit consisting of one share of Common Stock and the right to receive one Common Warrant upon, and subject to, stockholder approval of the issuance thereof, was $2.585 per Unit. The combined purchase price for a Pre-Funded Warrant and the right to receive one Common Warrant upon, and subject to, stockholder approval of the issuance thereof, was $2.5849 per Unit. The Pre-Funded Warrants have an exercise price of $0.0001 per share of Common Stock, are exercisable immediately and will not expire until exercised in full. The Common Warrants will have an exercise price of $2.585 per share and will expire on the five and one half (5.5) year anniversary of their issuance. Under Nasdaq Listing Rule 5635(d), the Company is required to obtain stockholder approval before issuing the Common Warrants because the potential issuance of shares upon exercise of the Common Warrants could exceed the thresholds set forth in such rule. Following receipt of stockholder approval, the Company will issue the Common Warrants to the Investors in accordance with the Purchase Agreement.

The Company intends to use the net proceeds from this Offering to continue clinical trials for HCW9302, advance its IND-enabling studies for its T-Cell Engager, HCW11-018b, and its second-generation immune checkpoint inhibitor, HCW11-040, and for general corporate purposes.

On July 29, 2026, the Company also entered into a registration rights agreement with the Investors, pursuant to which the Company agreed to submit to the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-1 within 15 trading days of the closing of the Offering covering the resale of the shares of Common Stock sold in the Offering, the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants and the shares of Common Stock issuable upon exercise of the Common Warrants. The Company also agreed to use commercially reasonable efforts to cause the registration statement to be declared effective by the SEC within 60 days following the closing of the Offering.

The number of shares of Common Stock the Company that may be held by an Investor, including those shares issued at closing and upon the exercise of Pre-Funded Warrants from time to time in the Offering, may not exceed 9.99% of the number of shares of the Company’s Common Stock outstanding immediately after giving effect to such issuances.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About HCW Biologics:

HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to treat diseases promoted by chronic inflammation, including autoimmune diseases, cancer, and senescence-associated dysplasia. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of proinflammatory and senescence-associated diseases and conditions that are promoted by chronic inflammation —and in doing so, improve patients’ quality of life and possibly extend longevity. A key aspect of the Company’s clinical development and financing strategy is to focus on its business development programs. See the Company Pipeline at https://hcwbiologics.com/pipeline/

Forward Looking Statements:

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words and include, without limitation, statements regarding the completion of the Offering and the satisfaction of customary closing conditions; the anticipated use of proceeds from the Offering; the Company's ability to obtain stockholder approval for the issuance of the Common Warrants; the anticipated issuance of the Common Warrants following receipt of stockholder approval; the anticipated filing and effectiveness of registration statements covering the shares of Common Stock issued in the Offering; and the prospective efficacy and success of the Company’s immunotherapeutic candidates and development programs.. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties that are described in the section titled “Risk Factors” in the annual report on Form 10-K filed with the SEC on March 31, 2026, and in other filings filed from time to time with the SEC.

Company Contact:
Rebecca Byam
Chief Financial Officer
rebeccabyam@hcwbiologics.com

FAQ

What are the key terms of HCW Biologics (NASDAQ: HCWB) $1.6 million private placement announced July 29, 2026?

HCW Biologics priced a $1.6 million private placement of 618,682 units with institutional and insider investors. According to the company, each unit includes one common share or pre-funded warrant and the right to receive one common warrant, subject to stockholder approval and customary closing conditions.

How many shares and warrants are issued in the July 2026 HCW Biologics (HCWB) private placement?

The offering covers 618,682 units, including 218,682 common shares and 400,000 pre-funded warrants. According to HCW Biologics, investors may also receive common warrants to purchase up to an additional 618,682 shares, contingent on stockholder approval under Nasdaq Listing Rule 5635(d).

What will HCW Biologics use the proceeds from the 2026 HCWB $1.6 million private placement for?

HCW Biologics plans to use the net proceeds primarily to support R&D programs. According to the company, funds will continue the HCW9302 clinical trial, advance IND-enabling studies for T-Cell Engager HCW11-018b and immune checkpoint inhibitor HCW11-040, and cover general corporate purposes.

How does stockholder approval affect the common warrants in the HCW Biologics (HCWB) 2026 private placement?

Stockholder approval is required before HCW Biologics can issue the common warrants. According to the company, Nasdaq Rule 5635(d) triggers this requirement because warrant exercises could exceed specified issuance thresholds, so common warrants are deliverable only after such approval is obtained.

What are the exercise prices and durations of HCW Biologics (HCWB) pre-funded and common warrants in the 2026 offering?

Pre-funded warrants are exercisable immediately at $0.0001 per share and do not expire until fully exercised. According to HCW Biologics, common warrants will have a $2.585 exercise price per share and will expire 5.5 years after their issuance, following stockholder approval.

When will HCW Biologics register the resale of HCWB shares from the 2026 private placement?

HCW Biologics agreed to file a Form S-1 registration statement within 15 trading days after closing. According to the company, it will use commercially reasonable efforts to obtain SEC effectiveness within 60 days, covering shares and warrant-related issuances from the offering.

Does the July 2026 HCW Biologics (HCWB) private placement limit how much stock each investor can own?

Yes, investor ownership is capped at 9.99% of outstanding common shares after issuances. According to HCW Biologics, this limit applies to shares held at closing and shares obtained through exercising pre-funded warrants, helping manage concentration and potential control implications for individual investors.